2013 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
07/31/13AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
SKOKIE, Ill., July 31, 2013 /PRNewswire/ -- AuraSense Therapeutics, a biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulation and modulation agents for a variety of diseases, including applications in oncology, dermatology, neurology, and for immune disorders, has closed the second tranche of its Series B financing.  The investment adds to the initial Series B round completed in December 2011.  Investors in the Series B round include AbbVie... 
Printer Friendly Version
03/31/13Sergei Gryaznov PhD Joins AuraSense Therapeutics as Chief Technology Officer
AuraSense Therapeutics is pleased to announce our new Chief Technical Officer, Dr. Sergei Gryaznov. Dr. Gryaznov is an internationally recognized scientist and expert in the areas of telomerase, oncology, nucleosides, nucleotides, DNA & RNA analogues, lipid and peptide conjugates, small molecules and nucleic acid based therapeutic agents. His efforts will be instrumental in accelerating the SNA platform into multiple core development programs.Dr. Gryaznov worked as the Director of Chemistry ... 
Printer Friendly Version
02/28/13AuraSense Therapeutics Announces Election of David Walt to Board of Managers
AuraSense Therapeutics is pleased to announce the election of Dr. David R. Walt to its Board of Managers. David R. Walt is Robinson Professor of Chemistry and Professor of Biomedical Engineering at Tufts University and is a Howard Hughes Medical Institute Professor. Dr. Walt served as the Chemistry Department Chairman at Tufts from 1989 to 1996. His laboratory is renowned for its pioneering work that applies micro- and nano-technology to urgent biological problems such as the analysis of genetic... 
Printer Friendly Version

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet